Medullary thyroid cancer
1 paper1 finding
- Human trial1
Interventions
1Everolimus
downin humans1
1 study
Everolimus
downin humans1
Everolimus decreases medullary thyroid cancer in humans.
“A tumour response was observed in both patients.”
Human trialin combination with octreotide LAR5-10 mg/dayn = 2
Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study
Journal of cellular and molecular medicine1 Jul 2012
Trial sponsors
Company1 trialPhase 1/2200 people
H. Lee Moffitt Cancer Center and Research Institute
1 trialPhase 26 people
University of Wisconsin-madison
1 trialPhase 25 people
Latest
ENDO 2025 Abstract
SUN-344 Much Ado About Nothing: Tirzepatide and Medullary Thyroid Cancer Debunked
Cohort study in peopleTirzepatide
Journal of Cellular and Molecular Medicine
Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study
Trial in 2 peoplemTOR inhibitors